Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial

Fig. 2

Glycaemic control a HbA1c over time [mixed model repeated measures (MMRM) in the full analysis set (FAS), observed cases (OC)]. b Patients with HbA1c ≥7 % at baseline who had HbA1c <7 % at week 76 (logistic regression in patients from the FAS treated in the extension trial using non-completers considered failures approach). c Change from baseline in FPG over time (MMRM in the FAS, OC). Empagliflozin 10 mg versus placebo odds ratio 4.17 (95 % CI 2.31, 7.51); empagliflozin 25 mg versus placebo odds ratio 3.96 (95 % CI 2.20, 7.14); sitagliptin versus placebo odds ratio 2.42 (95 % CI 1.32, 4.43). Empagliflozin 10 mg versus sitagliptin odds ratio 1.72 (95 % CI 1.04, 2.86); empagliflozin 25 mg versus sitagliptin odds ratio 1.64 (95 % CI 0.99, 2.72)

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840